Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 5 May 2008 |
| Genmab's Total Number of Voting Rights and Total Share Capital | 30 Apr 2008 |
| Major Shareholder Announcement for Genmab A/S | 28 Apr 2008 |
| Constitution of the Board of Directors in Genmab and Grant of Warrants to Employees and a Member of Management | 24 Apr 2008 |
| Report Pursuant to Section 28a of the Danish Securities Trading Act | 24 Apr 2008 |